Below are the most recent publications written about "Factor VIII" by people in Profiles.
-
Curtis R, Roberts JC, Crook N, Decker-Palmer M, Khainar R, Baker JR, Ullman M, Koerper MA, Wu J, Nichol MB. Trends in prescribing practices for management of haemophilia: 1999-2021. Haemophilia. 2023 May; 29(3):761-769.
-
Tanaka KA, Henderson R, Thangaraju K, Morita Y, Mazzeffi MA, Strauss E, Katneni U, Buehler PW. In vitro effects of emicizumab on activated clotting time in blood samples from cardiac surgical patients. Haemophilia. 2022 Jan; 28(1):183-190.
-
Batty P, Riddell A, Kitchen S, Sardo Infirri S, Walker I, Woods T, Jennings I, Hart DP. Factor VIII/IX inhibitor testing practices in the United Kingdom: Results of a UKHCDO and UKNEQAS national survey. Haemophilia. 2021 May; 27(3):490-499.
-
Lowe A, Kitchen S, Jennings I, Kitchen DP, Woods TAL, Walker ID. Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise. Haemophilia. 2020 Nov; 26(6):1087-1091.
-
Kurian CJ, Drelich DA, Rizk S. Successful liver transplant from a hemophilia A donor with no development of hemophilia A in recipient. J Thromb Haemost. 2020 04; 18(4):853-856.
-
Kitchen S, Jennings I, Makris M, Kitchen DP, Woods TAL, Walker ID. Clotting and chromogenic factor VIII assay variability in post-infusion and spiked samples containing full-length recombinant FVIII or recombinant factor VIII Fc fusion protein (rFVIIIFc). Int J Lab Hematol. 2019 Apr; 41(2):176-183.
-
Kitchen S, Jennings I, Makris M, Kitchen DP, Woods TA, Walker ID. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII. Haemophilia. 2016 Sep; 22(5):806-12.
-
Matino D, Gargaro M, Santagostino E, Di Minno MN, Castaman G, Morfini M, Rocino A, Mancuso ME, Di Minno G, Coppola A, Talesa VN, Volpi C, Vacca C, Orabona C, Iannitti R, Mazzucconi MG, Santoro C, Tosti A, Chiappalupi S, Sorci G, Tagariello G, Belvini D, Radossi P, Landolfi R, Fuchs D, Boon L, Pirro M, Marchesini E, Grohmann U, Puccetti P, Iorio A, Fallarino F. IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. J Clin Invest. 2015 Oct 01; 125(10):3766-81.
-
Oldenburg J, Albert T. Novel products for haemostasis - current status. Haemophilia. 2014 May; 20 Suppl 4:23-8.
-
Ivaskevicius V, Goldmann G, Horneff S, Marquardt N, Klein C, Albert T, Zeitler H, Oldenburg J. Inhibitor development and management in three non-severe haemophilia A patients with T295A variant. Hamostaseologie. 2014; 34 Suppl 1:S9-12.